Welcome to Our Medtech Talk Podcast Channel

Too often we define the Medtech sector by the number of dollars raised, IPOs helped or companies sold. But the focus neglects the very foundation of the sector - the People. Join the Medtech Talk Podcast each week to hear from entrepreneurs, investors and executives who spend their days developing the tools that make sick people well and health care more efficient.



Newly Minted VC Stacy Enxing Seng Talks Medtech, Medtronic & Why She Joined Lightstone

April 28, 2016

 

Though initially surprised by Medtronic’s move to buy Covidien, Stacy Enxing Seng says she immediately saw the wisdom of the deal and recognized the opportunity for a fresh start. In an interview, Enxing Seng explains why she left, what she’s been doing, and how her new role at Lightstone Ventures fits her vision for Medtech’s future.

 

Stacy Enxing Seng

Venture Partner & Independent Director

Lightstone Ventures

Stacy currently serves as a Venture Partner with Lightstone Ventures as well as an Independent Director for both public and venture-backed private companies. Prior to Venture/Independent Director work, Stacy spent the last 25 years in medtech, most recently serving as the President of Covidien¹s $1.7B Vascular business. Stacy joined Covidien following its $2.6B acquisition of ev3 Inc., a medtech success that Stacy co-created in 2000 with ev3¹s founding team. Stacy has been involved in the launch of over 20 medtech technologies, more than 10 substantive M&A transactions, and under her operating leadership, a reputation of achieving world class customer and employee engagement. Stacy currently serves as a non-executive Independent Director for Hill-Rom Holdings, Inc., (NYSE: HRC), Sonova Holding AG (VTX: SOON), and private Spirox, Inc. and Solace Therapeutics. Past Director appointments include FIRE 1 and CVI. Stacy holds a B.A. Public Policy, Michigan State University and an M.B.A. Harvard University.

Meet Our Host, Geoff Pardo

Geoff has been in medtech for over two decades in both operational and investment roles. He is passionate about the industry potential and sharing stories from the front lines of innovation.